Director/PDMR Shareholding

RNS Number : 9289C
Zotefoams PLC
22 October 2020
 

Zotefoams plc

(the 'Company')

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs

On 20 October 2020, the Company received notice from its Employee Benefit Trust of the exercise and partial sale for tax of nil cost options granted over ordinary shares of 5 pence each ('Shares') under the Company's Deferred Bonus Share Plan ('DBSP') by Mr J P Bridges as follows:

Total number of shares sold

Number of shares sold for tax

Aggregated Sale price (£)

10,934

5138

£4.29

 

Awards granted under the DBSP usually vest three years from grant, subject to satisfaction of service conditions. However, given the unprecedented circumstances brought about by COVID-19, and the decision of the Board not to recommend a final dividend for the year ended 31 December 2019, the proportion of the bonus that would normally have been paid in cash was deferred into shares (the 'Deferred Bonus proportion'). The Remuneration Committee approved the exercise of the Deferred Bonus proportion with effect from 20 October 2020 for non-Board PDMRs. The proportion of the bonus that would normally be deferred into shares (25%) will continue as normal and will be released after three years.

The award was increased to reflect the dividend paid during the restricted period.

The Notification of Dealing Form can be found below.

 

This announcement is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation 596/2014.

 

Lydia Harratt

Group Company Secretary

Zotefoams plc

020 8664 1600

 

22 October 2020

 

About Zotefoams plc

 

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2021.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.



 

ZOTEFOAMS PLC

DEALING NOTIFICATION FORM
FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: James Peter Bridges

2.

Reason for the notification

a)

Position/status: Senior Executive

b)

Initial notification/Amendment: Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:  Zotefoams plc

b)

LEI: 213800B6P256B5XN8D32

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise and sale of shares under the Deferred Bonus Share Plan

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£4.291950

2,300

£4.20

1,000

£4.30

7,583

£4.27

51

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£4.29

10,934

£46,906.86

e)

Date of the transaction: 20 October 2020

f)

Place of the transaction: XLON

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEANEAADDEFEA

Companies

Zotefoams (ZTF)
UK 100